ArticleLiver cancer2023

Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety.

Philippe Merle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.